Paper Details

  1. Home
  2. Paper Details

Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).

Author: BorchmannPeter, BröckelmannPaul J, DiehlVolker, EichenauerDennis A, EngertAndreas, FuchsMichael, GillessenSarah, GreilRichard, MarkovaJana, MeissnerJulia, PlütschowAnnette, ToppMax S, ZijlstraJosée M, von TresckowBastian

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study followed up on a previous trial that compared two different chemotherapy regimens for early-stage Hodgkin lymphoma. While the more intensive regimen (escalated BEACOPP followed by ABVD) showed a benefit in preventing disease recurrence in the short term, there was no difference in overall survival between the two groups. This follow-up analysis aimed to evaluate the long-term effectiveness and side effects of this treatment approach.
Paper Details　
Original Abstract of the Article :
To improve the long-term tumour control in early, unfavourable Hodgkin Lymphoma, the German Hodgkin Study Group (GHSG) HD14 trial compared four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with an intensified chemotherapy regimen consisting of two cycles of escalated bleomyc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3026(21)00029-6

データ提供：米国国立医学図書館（NLM）

Intensified Treatment for Hodgkin Lymphoma: A Long-Term Perspective

Hodgkin lymphoma is a type of cancer that affects the lymphatic system. While there have been significant advancements in treating this disease, some patients face challenges with long-term control of the cancer. This study, conducted by the German Hodgkin Study Group (GHSG), focused on a long-term follow-up analysis of a randomized phase 3 trial comparing two chemotherapy regimens for patients with early-stage, unfavorable Hodgkin lymphoma.

Intensified Therapy Provides Long-Term Benefit

The study found that patients who received an intensified chemotherapy regimen consisting of two cycles of escalated BEACOPP plus two cycles of ABVD had a significant advantage in terms of freedom from treatment failure at five years. However, there was no difference in overall survival between the two groups. This indicates that the intensified treatment strategy led to a longer period without the cancer returning, but did not ultimately affect overall survival.

What Does This Mean for Patients with Hodgkin Lymphoma?

This research suggests that intensified chemotherapy can be beneficial in achieving longer periods of remission for patients with early-stage, unfavorable Hodgkin lymphoma. However, it's important to note that more research is needed to determine the long-term impact of this strategy on overall survival and to understand the potential risks and benefits of this approach.

Dr.Camel's Conclusion

This study provides valuable insights into the long-term effects of intensified chemotherapy in Hodgkin lymphoma. It's like a compass guiding us towards a more nuanced understanding of cancer treatment strategies. While the intensified regimen appears to offer a temporary advantage, we must continue our quest for truly effective therapies that address the root of the disease and offer lasting benefits for patients.

Date :
  1. Date Completed 2021-04-01
  2. Date Revised 2021-04-01
Further Info :

Pubmed ID

33770483

DOI: Digital Object Identifier

10.1016/S2352-3026(21)00029-6

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.